776 related articles for article (PubMed ID: 25611208)
21. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
Aroor AR; Das NA; Carpenter AJ; Habibi J; Jia G; Ramirez-Perez FI; Martinez-Lemus L; Manrique-Acevedo CM; Hayden MR; Duta C; Nistala R; Mayoux E; Padilla J; Chandrasekar B; DeMarco VG
Cardiovasc Diabetol; 2018 Jul; 17(1):108. PubMed ID: 30060748
[TBL] [Abstract][Full Text] [Related]
22. DNA aptamer raised against advanced glycation end products (AGEs) improves glycemic control and decreases adipocyte size in fructose-fed rats by suppressing AGE-RAGE axis.
Ojima A; Matsui T; Nakamura N; Higashimoto Y; Ueda S; Fukami K; Okuda S; Yamagishi S
Horm Metab Res; 2015 Apr; 47(4):253-8. PubMed ID: 25105541
[TBL] [Abstract][Full Text] [Related]
23. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice.
Lin B; Koibuchi N; Hasegawa Y; Sueta D; Toyama K; Uekawa K; Ma M; Nakagawa T; Kusaka H; Kim-Mitsuyama S
Cardiovasc Diabetol; 2014 Oct; 13():148. PubMed ID: 25344694
[TBL] [Abstract][Full Text] [Related]
24. Tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, suppresses renal damage in KKAy/Ta mice, obese and type 2 diabetic animals.
Ishibashi Y; Matsui T; Yamagishi SI
Diab Vasc Dis Res; 2016 Nov; 13(6):438-441. PubMed ID: 27407083
[TBL] [Abstract][Full Text] [Related]
25. The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin.
Kern M; Klöting N; Mark M; Mayoux E; Klein T; Blüher M
Metabolism; 2016 Feb; 65(2):114-23. PubMed ID: 26773934
[TBL] [Abstract][Full Text] [Related]
26. Renoprotection of dapagliflozin in human renal proximal tubular cells via the inhibition of the high mobility group box 1‑receptor for advanced glycation end products‑nuclear factor‑κB signaling pathway.
Yao D; Wang S; Wang M; Lu W
Mol Med Rep; 2018 Oct; 18(4):3625-3630. PubMed ID: 30132524
[TBL] [Abstract][Full Text] [Related]
27. SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice.
Xu L; Nagata N; Nagashimada M; Zhuge F; Ni Y; Chen G; Mayoux E; Kaneko S; Ota T
EBioMedicine; 2017 Jun; 20():137-149. PubMed ID: 28579299
[TBL] [Abstract][Full Text] [Related]
28. Empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK).
Domon A; Katayama K; Sato T; Tochigi Y; Tazaki H; Suzuki H
PLoS One; 2021; 16(5):e0251135. PubMed ID: 33945582
[TBL] [Abstract][Full Text] [Related]
29. The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes.
Cheng ST; Chen L; Li SY; Mayoux E; Leung PS
PLoS One; 2016; 11(1):e0147391. PubMed ID: 26807719
[TBL] [Abstract][Full Text] [Related]
30. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice.
Terami N; Ogawa D; Tachibana H; Hatanaka T; Wada J; Nakatsuka A; Eguchi J; Horiguchi CS; Nishii N; Yamada H; Takei K; Makino H
PLoS One; 2014; 9(6):e100777. PubMed ID: 24960177
[TBL] [Abstract][Full Text] [Related]
31. Effects of the SGLT2 inhibitor ipragliflozin on various diabetic symptoms and progression of overt nephropathy in type 2 diabetic mice.
Tahara A; Takasu T
Naunyn Schmiedebergs Arch Pharmacol; 2018 Apr; 391(4):395-406. PubMed ID: 29374293
[TBL] [Abstract][Full Text] [Related]
32. Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy.
Lee YH; Kim SH; Kang JM; Heo JH; Kim DJ; Park SH; Sung M; Kim J; Oh J; Yang DH; Lee SH; Lee SY
Am J Physiol Renal Physiol; 2019 Oct; 317(4):F767-F780. PubMed ID: 31390268
[TBL] [Abstract][Full Text] [Related]
33. Nifedipine inhibits advanced glycation end products (AGEs) and their receptor (RAGE) interaction-mediated proximal tubular cell injury via peroxisome proliferator-activated receptor-gamma activation.
Matsui T; Yamagishi S; Takeuchi M; Ueda S; Fukami K; Okuda S
Biochem Biophys Res Commun; 2010 Jul; 398(2):326-30. PubMed ID: 20599709
[TBL] [Abstract][Full Text] [Related]
34. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.
Grempler R; Thomas L; Eckhardt M; Himmelsbach F; Sauer A; Sharp DE; Bakker RA; Mark M; Klein T; Eickelmann P
Diabetes Obes Metab; 2012 Jan; 14(1):83-90. PubMed ID: 21985634
[TBL] [Abstract][Full Text] [Related]
35. RAGE-Aptamer Blocks the Development and Progression of Experimental Diabetic Nephropathy.
Matsui T; Higashimoto Y; Nishino Y; Nakamura N; Fukami K; Yamagishi SI
Diabetes; 2017 Jun; 66(6):1683-1695. PubMed ID: 28385802
[TBL] [Abstract][Full Text] [Related]
36. Protective effects of oxymatrine on experimental diabetic nephropathy.
Guo C; Han F; Zhang C; Xiao W; Yang Z
Planta Med; 2014 Mar; 80(4):269-76. PubMed ID: 24535719
[TBL] [Abstract][Full Text] [Related]
37. Polydatin promotes Nrf2-ARE anti-oxidative pathway through activating Sirt1 to resist AGEs-induced upregulation of fibronetin and transforming growth factor-β1 in rat glomerular messangial cells.
Huang K; Chen C; Hao J; Huang J; Wang S; Liu P; Huang H
Mol Cell Endocrinol; 2015 Jan; 399():178-89. PubMed ID: 25192797
[TBL] [Abstract][Full Text] [Related]
38. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
Cherney DZ; Perkins BA; Soleymanlou N; Maione M; Lai V; Lee A; Fagan NM; Woerle HJ; Johansen OE; Broedl UC; von Eynatten M
Circulation; 2014 Feb; 129(5):587-97. PubMed ID: 24334175
[TBL] [Abstract][Full Text] [Related]
39. Nonclinical safety of the sodium-glucose cotransporter 2 inhibitor empagliflozin.
Bogdanffy MS; Stachlewitz RF; van Tongeren S; Knight B; Sharp DE; Ku W; Hart SE; Blanchard K
Int J Toxicol; 2014; 33(6):436-49. PubMed ID: 25260362
[TBL] [Abstract][Full Text] [Related]
40. Gene expression of receptor for advanced glycosylation end products and its modulation by aminoguanidine in diabetic kidney tissue.
Huang Y; Lin S; Zhou J
Chin Med J (Engl); 1998 Aug; 111(8):698-704. PubMed ID: 11245022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
